Skip to content

Spinal and Supra-Spinal Pain Mechanisms in Patients With Fibromyalgia

Spinal and Supra-Spinal Pain Mechanisms in Patients With Fibromyalgia

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03464292
Enrollment
55
Registered
2018-03-14
Start date
2018-07-05
Completion date
2023-12-08
Last updated
2023-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia, Pain

Brief summary

Fibromyalgia (FM) patients have increased windup (WU). However, WU of FM patients is only quantitatively but not qualitatively different from healthy controls (HC). Thus WU abnormalities of FM patients could be the result of supra-spinal and not the result of spinal pain mechanisms. The study team will test this hypothesis by sensitizing FM patients with topical capsaicin.

Detailed description

The study team hypothesizes that at baseline the slopes of sensitivity adjusted WU of FM patients are not statistically different from HC. However, after capsaicin application, the slopes of sensitivity adjusted WU will be significantly different from baseline and greater than those of HC, suggesting central sensitization. This would imply that FM patients are sensitive to heat pain but not sensitized.

Interventions

DRUGCapsaicin Patch 8% or 0.1% Capsaicin Cream

0.1 ml of 8% capsaicin topical patch or 0.1% capsaicin cream

Control patch will be the same topical solution but will not contain capsaicin.

Sponsors

University of Florida
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* individuals diagnosed with fibromyalgia will have pain of duration \> 6 months and meeting the 1990 Research Diagnostic Criteria for FM (ACR). * healthy, pain-free age matched controls without chronic pain

Exclusion criteria

* Allergy to red chili peppers; * Pregnant; * Significant hearing loss; * Presence of chronic disease (e.g. cancer, cardiovascular disease, liver disease, kidney disease, diabetes, etc.). * FM patients must be willing to discontinue or hold their FM related medications for at least 5 half-lives.

Design outcomes

Primary

MeasureTime frameDescription
Progression of Temporal Summation of Second Pain2 hrA Peltier device (Pathway, Medoc) will be used to tap the skin surface with a 3 cm x 3 cm probe. The Peltier device will be used to provide very brief, repetitive, thermal stimuli (for approx. 1s) to the skin using computer controlled temperatures. Heat stimuli at intervals of 2.5 sec produce sensations of increasing pain (temporal summation), depending on the number of stimuli presented. The late sensations of warmth are delayed in onset by approximately 1.5 sec after the probe touches the skin, because the sensation depends upon stimulation of slowly conducting unmyelinated peripheral afferents.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026